http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 06:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SMITH+%26amp%3B+NEPHEW+PLC++++For%3A+Jun+11/26632185.html si-local-file:///var/storage/secattach/20260611/26632185.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SMITH+%26amp%3B+NEPHEW+PLC++++For%3A+Jun+11/26632185.html Thu, 11 Jun 2026 06:15:00 -0400 O.00391766 SN SNN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SMITH+%26amp%3B+NEPHEW+PLC++++For%3A+Jun+11/26632185.html si-local-file:///var/storage/secattach/20260611/26632185.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SMITH+%26amp%3B+NEPHEW+PLC++++For%3A+Jun+11/26632185.html Thu, 11 Jun 2026 06:15:00 -0400 O.00391766 SN SNN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SMITH+%26amp%3B+NEPHEW+PLC++++For%3A+Jun+11/26632185.html si-local-file:///var/storage/secattach/20260611/26632185.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SMITH+%26amp%3B+NEPHEW+PLC++++For%3A+Jun+11/26632185.html Thu, 11 Jun 2026 06:15:00 -0400 O.00391766 SN SNN http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Press+Releases/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html <p><strong>Issued on behalf of Conexeu Sciences Inc.</strong></p><p align="left">NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=s02fupgOkYBxjoRQYi6_Mtg0mh73_8fezLnRs6C8ccNeiZ1JBuI-EpNhgaTI5OdKipKrTEBxdu6xJrHFgD3Z8RUbeKJGPKBJj2GjLom9F1E=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (Nasdaq: CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further http://www.streetinsider.com/Globe+Newswire/A+Fresh+FDA+Catalyst+Is+Putting+Regenerative+Wound+Care+in+Focus/26621787.html Tue, 09 Jun 2026 09:54:59 -0400 CNXU CNXU CNXU IART IART MDXG MDXG SNN SNN http://www.streetinsider.com/Corporate+News/Smith%2BNephew+completes+first+surgeries+with+new+CORI+XT+robotics+platform/26616462.html <p>Smith+Nephew (NYSE: SNN) announced the completion of initial clinical cases using its CORI XT Handheld Robotics Platform for knee and shoulder joint replacement procedures.</p><p>The first shoulder arthroplasty cases were performed at Duke Health by Dr. Christopher Klifto, utilizing the CORI SHOULDER system with the AETOS Shoulder System. Dr. Bertrand Kaper subsequently completed the first CORI XT shoulder procedures in an ambulatory surgery center at North Valley Surgery Center in Scottsdale, Arizona.</p><p>Dr. Ran Schwarzkopf performed the first knee replacement procedures with the CORI XT platform at NYU Langone Health.</p><p>The CORI XT Platform features a handheld design intended to provide robotic assistance http://www.streetinsider.com/Corporate+News/Smith%2BNephew+completes+first+surgeries+with+new+CORI+XT+robotics+platform/26616462.html Mon, 08 Jun 2026 13:24:24 -0400 SNN http://www.streetinsider.com/Press+Releases/Smith%2BNephew+announces+first+clinical+cases+with+the+next+generation+CORI%E2%97%8AXT+Handheld+Robotics+Platform+across+knee+and+shoulder+arthroplasty/26616455.html <p><br/></p> <p><b>Smith+Nephew</b> (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation <b>CORI◊ XT Handheld Robotics Platform</b>, marking an important milestone in the clinical introduction of its latest handheld robotics technology.</p> <p><img alt="" height="225" src="https://ml-eu.globenewswire.com/Resource/Download/8e98d230-2847-494c-936f-8f6e5b0226c6/cori-handheld-robotics-platform.jpg" width="400" data-dpi="300" data-filename="CORI Handheld Robotics Platform.jpg"/><br/>CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings. These early cases http://www.streetinsider.com/Press+Releases/Smith%2BNephew+announces+first+clinical+cases+with+the+next+generation+CORI%E2%97%8AXT+Handheld+Robotics+Platform+across+knee+and+shoulder+arthroplasty/26616455.html Mon, 08 Jun 2026 13:22:00 -0400 A.38717110 O.00391766 O.00865637 SN SNN http://www.streetinsider.com/Press+Releases/Smith%2BNephew+announces+first+clinical+cases+with+the+next+generation+CORI%E2%97%8AXT+Handheld+Robotics+Platform+across+knee+and+shoulder+arthroplasty/26616455.html <p><br/></p> <p><b>Smith+Nephew</b> (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation <b>CORI◊ XT Handheld Robotics Platform</b>, marking an important milestone in the clinical introduction of its latest handheld robotics technology.</p> <p><img alt="" height="225" src="https://ml-eu.globenewswire.com/Resource/Download/8e98d230-2847-494c-936f-8f6e5b0226c6/cori-handheld-robotics-platform.jpg" width="400" data-dpi="300" data-filename="CORI Handheld Robotics Platform.jpg"/><br/>CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings. These early cases http://www.streetinsider.com/Press+Releases/Smith%2BNephew+announces+first+clinical+cases+with+the+next+generation+CORI%E2%97%8AXT+Handheld+Robotics+Platform+across+knee+and+shoulder+arthroplasty/26616455.html Mon, 08 Jun 2026 13:22:00 -0400 A.38717110 O.00391766 O.00865637 SN SNN http://www.streetinsider.com/Press+Releases/Smith%2BNephew+announces+first+clinical+cases+with+the+next+generation+CORI%E2%97%8AXT+Handheld+Robotics+Platform+across+knee+and+shoulder+arthroplasty/26616455.html <p><br/></p> <p><b>Smith+Nephew</b> (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation <b>CORI◊ XT Handheld Robotics Platform</b>, marking an important milestone in the clinical introduction of its latest handheld robotics technology.</p> <p><img alt="" height="225" src="https://ml-eu.globenewswire.com/Resource/Download/8e98d230-2847-494c-936f-8f6e5b0226c6/cori-handheld-robotics-platform.jpg" width="400" data-dpi="300" data-filename="CORI Handheld Robotics Platform.jpg"/><br/>CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings. These early cases http://www.streetinsider.com/Press+Releases/Smith%2BNephew+announces+first+clinical+cases+with+the+next+generation+CORI%E2%97%8AXT+Handheld+Robotics+Platform+across+knee+and+shoulder+arthroplasty/26616455.html Mon, 08 Jun 2026 13:22:00 -0400 A.38717110 O.00391766 O.00865637 SN SNN